**Amendments to the Claims:** 

The following listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:** 

1. (Currently amended) A liquid vaccine composition comprising at least one antigen consisting

of a polysaccharide bound to a carrier protein, and further comprising trehalose, wherein the

immunogenicity of the protein-linked polysaccharide in the composition is preserved to a

greater extent over time as compared to the immunogenicity of the protein-linked

polysaccharide alone in a corresponding vaccine composition not containing trehalose, and

wherein the vaccine composition is maintained in a liquid state.

2. (Previously presented) The vaccine composition as claimed in claim 1, wherein said

polysaccharide is the capsular polysaccharide of Haemophilus influenzae type b or

Polyribosylribitol Phosphate.

3. (Previously presented) The vaccine composition as claimed in claim 1, wherein said

polysaccharide is a pneumococcal polysaccharide.

4. (Previously presented) The vaccine composition as claimed in claim 1, wherein said

polysaccharide is a meningococcal polysaccharide

5. (Previously presented) The vaccine composition as claimed in claim 1, wherein the said

carrier protein is tetanus toxoid.

6. (Previously presented) The vaccine composition as claimed in claim 1, wherein said carrier

protein is diphtheria toxoid.

7. (Previously presented) The vaccine composition as claimed in claim 1, wherein the quantity

of trehalose is between 3 and 12% by mass.

8. (Previously presented) The vaccine composition as claimed in claim 1, wherein the quantity

of trehalose is about 5%.

2

Application No. 09/937,103 Attorney Docket No. 01-1081

- 9. (Previously presented) A method of preserving the immunogenicity over time of a liquid vaccine composition comprising at least one antigen consisting of a polysaccharide bound to a carrier protein, wherein the method comprises adding trehalose to the vaccine composition, and maintaining the vaccine composition in a liquid state.
- 10. (Previously presented) The method as claimed in claim 9, wherein the quantity of trehalose to be added is between 3 and 12% by mass.
- 11. (Previously presented) The vaccine composition as claimed in claim 7, wherein said polysaccharaide is the capsular polysaccharide of *Haemophilus influenzae* type b or Polyribosylribitol Phosphate.
- 12. (Previously presented) The vaccine composition as claimed in claim 7, wherein said polysaccharide is a pneumococcal polysaccharide.
- 13. (Previously presented) The vaccine composition as claimed in claim 7, wherein said polysaccharide is a meningococcal polysaccharide
- 14. (Previously presented) The vaccine composition as claimed in claim 7, wherein the said carrier protein is tetanus toxoid.
- 15. (Previously presented) The vaccine composition as claimed in claim 7, wherein said carrier protein is diphtheria toxoid.
- 16. (Previously presented) The method of claim 10, wherein the quantity of trehalose is about 5% by mass.